STAT3 (Ab-727) Antibody

What is the specific epitope recognized by STAT3 (Ab-727) Antibody?

STAT3 (Ab-727) Antibody recognizes a peptide sequence around amino acids 725-729 (P-M-S-P-R) derived from Human STAT3. This antibody detects endogenous levels of total STAT3 protein regardless of phosphorylation status. The epitope is located in the C-terminal region of the protein, which is important for understanding cross-reactivity patterns and evaluating specificity when compared with other STAT3 antibodies targeting different regions .

What are the validated applications for STAT3 (Ab-727) Antibody?

The STAT3 (Ab-727) Antibody has been validated primarily for Western Blot (WB) and Immunohistochemistry (IHC) applications. For Western blot applications, optimal dilution ranges from 1:1000 to 1:2000, while for immunohistochemistry, the recommended dilution is 1:50 to 1:200. These applications enable detection of the total STAT3 protein in various tissue and cell lysate samples .

How should STAT3 (Ab-727) Antibody be stored and handled to maintain optimal activity?

For long-term preservation, store the antibody at -20°C (recommended). For short-term use, 4°C storage is acceptable. The antibody is supplied at 1.0mg/mL in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide, and 50% glycerol. Avoid repeated freeze-thaw cycles as they can denature the antibody and lead to decreased activity. When working with the antibody, maintain cold chain practices to preserve its binding capability .

How can I distinguish between phosphorylated and non-phosphorylated forms of STAT3 in my experiments?

To distinguish between phosphorylated and non-phosphorylated forms of STAT3:

• Use specific antibodies: STAT3 (Ab-727) detects total STAT3, while phospho-specific antibodies like phospho-STAT3 (S727) or phospho-STAT3 (Y705) detect only the phosphorylated forms.

• Perform parallel Western blots: Run identical samples on multiple blots and probe separately with total STAT3 and phospho-specific antibodies.

• Lambda phosphatase treatment: Treat half of your sample with lambda phosphatase to remove phosphorylation, then compare with untreated sample using phospho-specific antibodies as a control .

• Stimulation experiments: Compare samples from cells treated with stimuli known to induce STAT3 phosphorylation (e.g., IL-6, EGF) with untreated controls .

This approach allows quantification of the phosphorylation ratio (phospho-STAT3/total STAT3) to assess activation status accurately.

What are the optimal sample preparation protocols for detecting STAT3 with this antibody in Western blotting?

For optimal Western blot results with STAT3 (Ab-727) Antibody:

• Cell lysis: Use RIPA buffer supplemented with protease inhibitors and phosphatase inhibitors (critical if examining phosphorylation status).

• Protein quantification: Determine protein concentration using Bradford or BCA assay to ensure equal loading.

• Sample preparation:

  • Mix 20-30 μg protein with Laemmli buffer

  • Heat at 95°C for 5 minutes

  • Use fresh samples when possible

• Gel electrophoresis:

  • Use 8-10% SDS-PAGE gels (STAT3 is approximately 88 kDa but appears at 92-100 kDa)

  • Run at 70V (stacking gel) followed by 90V (resolving gel) for 2-3 hours

• Transfer and blocking:

  • Transfer to nitrocellulose membrane at 150 mA for 50-90 minutes

  • Block with 5% non-fat milk in TBS for 1.5 hours at room temperature

• Antibody incubation:

  • Dilute primary antibody 1:1000 in 5% milk/TBS

  • Incubate overnight at 4°C

  • Wash with TBS-0.1% Tween three times, 5 minutes each

  • Incubate with HRP-conjugated secondary antibody at 1:500-1:1000 for 1-1.5 hours

• Detection: Use enhanced chemiluminescence (ECL) detection system .

What controls should be included when using STAT3 (Ab-727) Antibody for immunohistochemistry?

For rigorous IHC experiments with STAT3 (Ab-727) Antibody, include the following controls:

• Positive tissue control: Use tissues known to express STAT3 (e.g., human liver, placenta, kidney, or pancreas) .

• Negative tissue control: Use tissues with minimal STAT3 expression.

• Technical negative control:

  • Primary antibody omission (replace with buffer)

  • Isotype control (replace with non-specific rabbit IgG)

• Peptide competition control: Pre-incubate antibody with immunizing peptide before staining to confirm specificity.

• Phosphorylation controls (if relevant):

  • Tissues/cells treated with phosphatase

  • Samples with known STAT3 activation status (e.g., IL-6 stimulated cells)

• STAT3 knockout/knockdown controls: If available, include tissue from STAT3 knockout models or cells with STAT3 siRNA treatment .

Optimal IHC protocol includes heat-mediated antigen retrieval using Tris-EDTA buffer (pH 9.0) prior to antibody incubation.

How can I differentiate between the functional impacts of STAT3 phosphorylation at Ser727 versus Tyr705 in my experimental system?

Differentiating between functional impacts of phosphorylation at different sites requires multi-faceted approaches:

• Site-specific antibodies: Use antibodies specifically targeting phospho-S727 and phospho-Y705 in parallel experiments.

• Mutagenesis studies: Generate STAT3 constructs with mutations at S727 (S727A) or Y705 (Y705F) that prevent phosphorylation at these sites.

• Kinase inhibitors: Use selective inhibitors:

  • JAK inhibitors primarily affect Y705 phosphorylation

  • MAPK/mTOR pathway inhibitors primarily affect S727 phosphorylation

• Stimulus-specific activation:

  • IL-6 predominantly induces Y705 phosphorylation

  • EGF can induce both sites with different kinetics

• Subcellular localization analysis: Y705 phosphorylation strongly promotes nuclear translocation, while S727 phosphorylation may have more subtle effects on localization.

• Functional readouts:

  • Transcriptional activity (luciferase reporter assays)

  • Target gene expression (qRT-PCR for STAT3 target genes)

  • Biological processes (proliferation, migration, EMT markers)

Recent research indicates that S727 and Y705 phosphorylation differentially regulate epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) in cancer stem cells, with Y705 phosphorylation promoting EMT and S727 phosphorylation promoting MET .

What are the common technical challenges in detecting STAT3 phosphorylation at Ser727 and how can they be overcome?

Common challenges and solutions for detecting STAT3 phosphorylation at Ser727:

Additional approaches include enriching phospho-proteins using phospho-protein purification kits prior to Western blotting to increase sensitivity, especially in samples with low STAT3 expression levels .

How can I effectively use STAT3 (Ab-727) Antibody in combination with phospho-specific antibodies to analyze STAT3 activation dynamics?

To effectively analyze STAT3 activation dynamics using multiple antibodies:

• Sequential blotting approach:

  • Run a single blot

  • Probe first with phospho-specific antibody (p-S727 or p-Y705)

  • Strip the membrane (validate stripping efficiency)

  • Reprobe with STAT3 (Ab-727) for total STAT3

  • Calculate phospho/total ratio for normalization

• Parallel blotting approach:

  • Run identical samples on multiple gels

  • Transfer and probe separate membranes with different antibodies

  • Use loading controls (e.g., β-actin) on each membrane

  • Normalize signals across blots

• Time-course experiments:

  • Stimulate cells for varying durations (0, 5, 15, 30, 60, 120 min)

  • Analyze both phosphorylation sites and total STAT3

  • Plot phosphorylation kinetics to detect site-specific activation patterns

• Multiplexed detection:

  • Use secondary antibodies with different fluorophores

  • Detect total STAT3 and phospho-STAT3 simultaneously

  • Analyze using fluorescence imaging systems

• Stimulus-specific responses:

  • Compare different activators (IL-6, EGF, IFN-α)

  • Analyze pathway-specific inhibitors

  • Create activation profiles for different stimuli

This combined approach provides comprehensive information about STAT3 activation status, helping distinguish between different signaling pathways that converge on STAT3 .

Why might I observe discrepancies between STAT3 detection using STAT3 (Ab-727) Antibody and other STAT3 antibodies?

Discrepancies between different STAT3 antibodies may arise from several factors:

• Epitope differences: STAT3 (Ab-727) targets the region around amino acids 725-729, while other antibodies may target different regions. Protein conformational changes or post-translational modifications might mask certain epitopes while leaving others accessible.

• Isoform specificity: STAT3 has multiple isoforms (including STAT3α and STAT3β). Some antibodies may preferentially detect specific isoforms, leading to apparent differences in detection.

• Protein interactions: STAT3 forms complexes with other proteins that may shield certain epitopes in specific cellular contexts or experimental conditions.

• Sample preparation effects: Different lysis buffers and denaturation conditions can affect epitope accessibility differently for various antibodies.

• Cross-reactivity profiles: Each antibody has unique cross-reactivity patterns with related proteins (e.g., other STAT family members).

To resolve discrepancies, validate findings with multiple antibodies targeting different STAT3 epitopes and employ complementary techniques such as mass spectrometry or siRNA knockdown controls .

How can I interpret conflicting results between phospho-STAT3 (S727) levels and functional readouts in my experiments?

When phospho-STAT3 (S727) levels don't correlate with expected functional outcomes:

• Consider signal pathway crosstalk:

  • S727 phosphorylation alone may be insufficient for full activation

  • Check Y705 phosphorylation status simultaneously

  • Examine upstream regulators (MAPK pathway components)

• Assess temporal dynamics:

  • Phosphorylation may be transient while functional effects persist

  • Perform detailed time-course experiments

  • Examine delayed responses after phosphorylation

• Evaluate additional post-translational modifications:

  • Acetylation, methylation, or SUMOylation may modulate STAT3 function

  • Use additional antibodies to detect these modifications

• Investigate nuclear translocation:

  • Perform nuclear/cytoplasmic fractionation

  • Use immunofluorescence to track STAT3 localization

• Examine cofactor availability:

  • STAT3 requires cofactors (e.g., CREB-binding protein) for transcriptional activity

  • Assess expression and activity of relevant cofactors

• Consider cell-type specificity:

  • The impact of S727 phosphorylation may vary between cell types

  • Compare your results with literature specific to your cell type

• Assess inhibitory mechanisms:

  • Check expression of negative regulators (e.g., PIAS3, SOCS3)

  • Evaluate protein phosphatases that may rapidly dephosphorylate STAT3

Recent research indicates that S727 and Y705 phosphorylation can have distinct and sometimes opposing functions in processes like EMT-MET transitions, which could explain apparently conflicting results .

What are the most reliable approaches to quantify changes in STAT3 phosphorylation at Ser727 in biological samples?

For reliable quantification of STAT3 Ser727 phosphorylation:

• Normalized Western blotting:

  • Always normalize phospho-STAT3 (S727) to total STAT3

  • Use technical replicates (minimum 3)

  • Include a standard curve of serial dilutions to ensure linearity of detection

  • Use digital imaging and specialized software (e.g., ImageJ) for densitometry

• Phospho-flow cytometry:

  • Provides single-cell resolution data

  • Allows analysis of heterogeneous populations

  • Enables multi-parameter analysis

  • Requires careful validation of antibody specificity

• ELISA-based approaches:

  • Commercial phospho-STAT3 (S727) ELISA kits

  • Higher throughput than Western blotting

  • More quantitative and reproducible

  • Less affected by technical variations

• Mass spectrometry:

  • Absolute quantification of phosphorylation stoichiometry

  • Can detect multiple phosphorylation sites simultaneously

  • Requires specialized equipment and expertise

  • Consider using isotope-labeled internal standards

• Proximity ligation assay (PLA):

  • In situ detection of phosphorylation

  • High specificity due to dual antibody requirement

  • Provides spatial information within cells

  • Amenable to quantitative image analysis

Regardless of method, always include appropriate controls:

• Positive controls (e.g., EGF or IL-6 stimulated cells)

• Negative controls (e.g., phosphatase-treated samples)

• Isotype controls for flow cytometry and immunostaining .

How does STAT3 Ser727 phosphorylation interact with other post-translational modifications to regulate STAT3 function?

STAT3 function is regulated by a complex interplay of post-translational modifications:

• Coordination with Tyr705 phosphorylation:

  • S727 phosphorylation can enhance transcriptional activity of Y705-phosphorylated STAT3

  • In some contexts, S727 phosphorylation can negatively regulate Y705 phosphorylation

  • The temporal sequence of phosphorylation events (S727 before or after Y705) can determine functional outcomes

• Interplay with acetylation:

  • STAT3 is acetylated at multiple lysine residues (K49, K87, K685)

  • K685 acetylation enhances STAT3 dimerization and DNA binding

  • S727 phosphorylation may influence recruitment of histone acetyltransferases

  • Combined acetylation and phosphorylation can synergistically enhance transcriptional activity

• Methylation effects:

  • Methylation at K140 by SET9 enhances STAT3 activity

  • S727 phosphorylation may regulate accessibility of methylation sites

• Ubiquitination and SUMOylation:

  • Regulate STAT3 protein stability and turnover

  • May be influenced by phosphorylation status at S727

  • Affect nuclear-cytoplasmic shuttling

• Redox regulation:

  • Oxidation of cysteine residues affects STAT3 activity

  • Phosphorylation status may influence sensitivity to redox conditions

These modifications form a "molecular barcode" that determines STAT3's protein interactions, subcellular localization, and target gene specificity. For comprehensive analysis, consider using proteomic approaches that can detect multiple modifications simultaneously .

What are the methodological considerations for studying STAT3 (Ab-727) in different cellular compartments and how does compartmentalization affect function?

Methodological considerations for studying STAT3 in different cellular compartments:

• Subcellular fractionation techniques:

  • Nuclear/cytoplasmic fractionation: Use NE-PER Nuclear and Cytoplasmic Extraction Reagents

  • Mitochondrial isolation: Use gradient centrifugation methods

  • Quality control: Verify fraction purity using compartment-specific markers (e.g., Lamin B for nucleus, GAPDH for cytosol)

• Immunofluorescence microscopy:

  • Fixation method matters: Paraformaldehyde (4%) preserves phospho-epitopes

  • Permeabilization: Triton X-100 (0.1%) allows antibody access while preserving structure

  • Co-staining: Use organelle markers (e.g., DAPI for nucleus, MitoTracker for mitochondria)

  • Super-resolution techniques for detailed localization studies

• Live-cell imaging:

  • STAT3-fluorescent protein fusions (e.g., STAT3-GFP)

  • Photo-activatable or photo-switchable tags for tracking movement

  • FRET-based sensors to detect conformational changes upon phosphorylation

• Proximity-based methods:

  • BioID or TurboID to identify compartment-specific interaction partners

  • PLA to visualize interactions in specific compartments

• Compartment-specific functions:

  • Nuclear STAT3: Primarily transcriptional regulation

  • Cytoplasmic STAT3: Scaffold for signaling complexes, regulates microtubule stability

  • Mitochondrial STAT3: Regulates electron transport chain, modulates ROS production

  • ER-associated STAT3: Regulates calcium homeostasis

When using STAT3 (Ab-727) Antibody for compartmental analysis, validate its ability to detect STAT3 in different fixation and permeabilization conditions, as some epitopes may be differentially accessible in distinct cellular compartments .

How can I design experiments to study the differential roles of STAT3 phosphorylation at Ser727 versus Tyr705 in epithelial-mesenchymal transition processes?

Experimental design for studying differential roles of STAT3 phosphorylation in EMT:

• Cell models and stimulation protocols:

  • Use epithelial cell lines with inducible EMT (e.g., A549, MCF-7)

  • Apply EMT inducers with different signaling pathways:

    • TGF-β (primarily Smad-dependent)

    • IL-6 (activates JAK/STAT, primarily Y705)

    • EGF (activates MAPK, can induce S727)

    • Hypoxia (complex effects on both sites)

• Genetic manipulation approaches:

  • Generate stable cell lines expressing:

    • Wild-type STAT3

    • STAT3-Y705F (prevents Y705 phosphorylation)

    • STAT3-S727A (prevents S727 phosphorylation)

    • STAT3-Y705F/S727A (double mutant)

  • Use CRISPR/Cas9 for endogenous STAT3 mutation

  • Consider tet-inducible systems for temporal control

• Functional readouts for EMT:

  EMT Parameter	Analytical Method	Expected Result
  Cell morphology	Bright-field microscopy	Mesenchymal cells show fibroblast-like appearance
  E-cadherin expression	Western blot, IF, qRT-PCR	Decreased in EMT
  N-cadherin expression	Western blot, IF, qRT-PCR	Increased in EMT
  Vimentin expression	Western blot, IF, qRT-PCR	Increased in EMT
  Cell migration	Wound healing, transwell assays	Enhanced in EMT
  Cell invasion	Matrigel invasion assay	Enhanced in EMT
  EMT transcription factors	qRT-PCR for SNAI1, TWIST1, ZEB1/2	Increased in EMT

• Kinetic analysis:

  • Temporal profiling of phosphorylation at both sites

  • Correlation with EMT marker expression

  • Use synchronization protocols to align cell populations

• Pathway inhibition:

  • JAK inhibitors (blocks Y705 phosphorylation)

  • MEK/ERK inhibitors (affects S727 phosphorylation)

  • mTOR inhibitors (affects S727 phosphorylation)

  • Assess EMT marker changes under inhibition conditions

• Single-cell analysis:

  • Single-cell phospho-flow cytometry

  • Single-cell RNA-seq with phospho-protein assays

  • Correlate phosphorylation status with EMT phenotype